The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects - The carmos study

Experimental and Clinical Endocrinology and Diabetes

Volumn 117, Issue 4, 2009, Pages 175-180

  Andreadis, E A ^a   Katsanou, P M ^a   Georgiopoulos, D X ^a   Tsourous, G I ^a   Yfanti, G K ^a   Gouveri, E T ^a   Diamantopoulos, E J ^a,b  

^a EVANGELISMOS HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Metabolic syndrome; Metformin; Prediabetes; Type 2 diabetes mellitus

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ANTIDIABETIC AGENT; CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; BLOOD; BODY SIZE; GREECE; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; METABOLIC SYNDROME X; MIDDLE AGED;

BODY MASS INDEX; BODY SIZE; CARDIOVASCULAR DISEASES; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; GREECE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; LIPIDS; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT; PREDIABETIC STATE; TRIGLYCERIDES;

EID: 67651212318     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0028-1087177     Document Type: Article

References (31)

1. Kuczmarski RI, Flegal KM, Campbell SM et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205
2. Sainaghi PP, Castello L, Bergamasco L et al. Metabolic characteristics of glucose intolerance: the critical role of obesity. Exp Clin Endocrinol Diabetes 2008; 116: 86-93
3. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005; 366: 1059-1062
4. Schwarz PE, Lindstrom J, Kissimova-Scarbeck K et al. DE-PLAN project. Exp Clin Endocrinol Diabetes 2008; 116: 167-172
5. Pfeiffer AF. Adipose tissue and diabetes therapy: do we hit the target? Horm Metab Res 2007; 39: 734-738
6. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone of the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized control trial. Lancet 2006; 368: 1096-1105
7. Chiasson JL, Josse RJ, Gomis R et al. Acarbose for prevention of type2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072-2077
8. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
9. Diamantopoulos EJ, Andreadis EA, Tsourous GI et al. Metabolic syndrome and prediabetes identify overlapping but not identical populations. Exp Clin Endocrinol Diabetes 2006; 114: 377-383
10. Diamantopoulos EJ, Andreadis EA, Tsourous GI et al. Intermediate postchallenge hyperglycemia in overweight and obese subjects: a new marker of impaired glucose regulation? Angiology 2006; 57: 709-716
11. Calle EE, Thun MJ, Petrelli JM et al. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341: 1097-1105
12. Friedwald WT, Levy RI, Fredrickson DS. Estimation of low-density lipoprotein cholesterol in plasma without use of the preparative ultra-centrifuge. Clin Chem 1972; 18: 499-502
13. Hainline A Jr, Karon J, Lippel K, eds. Manual of Laboratory Operations, ed. 2, Lipid Research Clinics Program, Lipid and Lipoprotein Analysis. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, (updated 1983)
14. Multicenter study of Tina-quant Albumin in urine and β-N- acetylglycosaminidase (β-NAG) in urine. Workshop Munich, November 29-30, 1990. Wien Klin Wschr 1991; 103 (Suppl. 189): 1-64
15. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2005; 28: S37-S42
16. The Food Guide Pyramid Washington, DC. Department of Agriculture, Center for Nutrition Policy and Promotion, 1996. (Home and Garden Bulletin no. 252.)
17. Step by step: eating to lower your high blood cholesterol. Bethesda, Md.: National Heart, Lung, and Blood Institute Information Center 1987
18. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Final report. Circulation 2002; 106: 3143-3421
19. Chobanian AV, Bakris GL, Black H et al. Seventh Report Of The Joint National Committee On Prevention, Detection, Evaluation, And Treatment Of High Blood Pressure. Hypertension 2003; 42: 1206-1252
20. Palumbo PJ. Metformin: Effects on cardiovascular risk factors in patients with Non-Insulin-Dependent Diabetes Mellitus. J Diab Complicat 1998; 12: 110-119 (Pubitemid 28156441)
21. Maglalhaes FO, Gouveia LM, Torquato MT et al. Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients. Horm Metab Res 2006; 38: 513-517
22. Kirpichnikov D, MacFarlane SI, Sowers JR. Metformin: An Update. Ann Intern Med 2002; 137: 25-33
23. Giugiliano D, Acampora R, DeRosa N et al. Metformin improves glucose lipid metabolism and reduces blood pressure in hypertensive obese women. Diabetes Care 1993; 16: 1387-1390
24. Stumvoll M, Nurjahan N, Perriello G et al. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554
25. Rains SGH, Wilson GA, Richmond W et al. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic Med 1988; 5: 653-658
26. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995; 333: 541-549
27. Wu MS, Johnston P, Sheu WH-H et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990; 13: 1-8
28. Landin K, Tengborn I, Smith U. Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med 1991; 229: 181-187
29. Nathan D, Davidson BM, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance. Implications for care. Diabetes Care 2007; 3: 753-759
30. Xiang GD, Sun HL, Hou J et al. Acute hyperglycemia rapidly suppresses endothelium-dependent arterial dilation in first-degree relatives of type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2008; 116: 112-117
31. Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes. An unmet challenge for cardiovascular risk reduction. Diabetes Care 2007; 30: 479-484